Scientists have identified BVES protein as a suppressor of colorectal cancer progression. Researchers believe that BVES could be a therapeutic or preventive target in colorectal cancer.
Cancers originating from cells covering any of the external and internal surfaces of the body (epithelial cells) are known as epithelial cancers. If such cancers (e.g., colorectal cancer) are to become invasive and spread to distant sites in the body, some of the epithelial cancer cells must acquire the characteristics of a different cell type, a mesenchymal cell. Protein complexes that link epithelial cells together (junctional complexes) are regulators of epithelial-mesenchymal transition (EMT). Chang, Williams, and colleagues found that the junctional protein BVES regulates EMT in human colon cancer cells. Importantly, the team found that BVES expression was reduced in all stages of human colorectal carcinoma and that restoring BVES expression to normal decreased the in vitro and in vivo cancer cell characteristics of human colon cancer cells. These data provide the rational for the suggestion that targeting BVES could be of benefit to individuals with colorectal cancer.